Literature DB >> 21172232

The prevalence of hyper- and hypothyroidism in patients with ulcerative colitis.

Giovanni Casella1, Elisabetta De Marco, Elisabetta Antonelli, Marco Daperno, Vittorio Baldini, Stefano Signorini, Federica Sannella, Antonio Morelli, Vincenzo Villanacci, Gabrio Bassotti.   

Abstract

BACKGROUND: The association between ulcerative colitis and thyroid disorders has been previously reported. However, most reports consist of single case description, and a systematic assessment of this relationship has only sporadically been investigated. AIMS: To study a cohort of patients with ulcerative colitis to establish the prevalence of hyper- and hypothyroidism.
MATERIAL AND METHODS: During a four-year period, we studied thyroid function in 162 ulcerative colitis patients (62 men, 100 women, age range 18-78 years).
RESULTS: Thyroid dysfunction was present in 4 patients (2.5%) of the overall population and was represented by both hypo- (3 patients) and hyperthyroidism (1 patient). The incidence of this kind of thyroid dysfunction was significantly (p=0.03) lower than that found in a large (more than 5000 subjects) control group.
CONCLUSIONS: We conclude that the prevalence of hyper-/hypothyroidism is relatively low in patients with ulcerative colitis, at least in our country, and does not justify a systematic investigation of the thyroid function, except in selected cases, probably those with scarce or no response to standard therapeutic measures.

Entities:  

Year:  2008        PMID: 21172232     DOI: 10.1016/j.crohns.2008.09.001

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  8 in total

1.  A double conundrum: concurrent presentation of Hashimoto's thyroiditis and ulcerative colitis.

Authors:  Gurpreet Singh; Susie Brien; Ellen Taylor
Journal:  BMJ Case Rep       Date:  2016-04-22

2.  Enzymatic activity of type 1 iodothyronine deiodinase in selected liver tumors.

Authors:  Oskar Kornasiewicz; Marcin Dębski; Michal Grat; Barbara Lenartowicz; Marta Stępnowska; Anna Szałas; Ewa Bar-Andziak; Marek Krawczyk
Journal:  Arch Med Sci       Date:  2013-08-20       Impact factor: 3.318

3.  Thyroid Dysfunction, Neurological Disorder and Immunosuppression as the Consequences of Long-term Combined Stress.

Authors:  Jingping Zhang; Jingjing Huang; Kasimujiang Aximujiang; Chenbo Xu; Abulaiti Ahemaiti; Guixia Wu; Li Zhong; Kurexi Yunusi
Journal:  Sci Rep       Date:  2018-03-14       Impact factor: 4.379

Review 4.  Inflammatory bowel disease and immune-mediated inflammatory diseases: looking at the less frequent associations.

Authors:  Cristina Bezzio; Cristina Della Corte; Marta Vernero; Imma Di Luna; Gianpiero Manes; Simone Saibeni
Journal:  Therap Adv Gastroenterol       Date:  2022-07-28       Impact factor: 4.802

5.  Understanding anti-TNF treatment failure: does serum triiodothyronine-to-thyroxine (T3/T4) ratio predict therapeutic outcome to anti-TNF therapies in biologic-naïve patients with active luminal Crohn's disease?

Authors:  Simeng Lin; Neil Chanchlani; Isabel Carbery; Malik Janjua; Rachel Nice; Timothy J McDonald; Claire Bewshea; Nicholas A Kennedy; Tariq Ahmad; Christian P Selinger; James R Goodhand
Journal:  Aliment Pharmacol Ther       Date:  2022-06-29       Impact factor: 9.524

6.  Papillary thyroid cancer and ulcerative colitis.

Authors:  Giovanni Casella; Elisabetta Antonelli; Camillo Di Bella; Vincenzo Villanacci; Mohammad Rostami Nejad; Vittorio Baldini; Gabrio Bassotti
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2013

Review 7.  Concomitant Thyroid Disorders and Inflammatory Bowel Disease: A Literature Review.

Authors:  Toru Shizuma
Journal:  Biomed Res Int       Date:  2016-03-03       Impact factor: 3.411

8.  Infliximab Therapy Could Decrease the Risk of the Development of Thyroid Disorders in Pediatric Patients With Crohn's Disease.

Authors:  Aleksandra Furtak; Anna Maria Wedrychowicz; Malgorzata Sladek; Andrzej Wedrychowicz; Krzysztof Fyderek; Jerzy Starzyk
Journal:  Front Endocrinol (Lausanne)       Date:  2020-09-15       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.